SBIR/STTR Research Award

SBIR Phase II: Enhancing Performance and Achieving Commercial Readiness for the PQS1.0 Rapid Phenylalanine Blood Level Monitor

Award identifier 348cc293d6c050ebab5e06598fe0897d5b8393d11213b3b3367a1ef83ba1416aAwarding agency National Science Foundation

Award amount

$997,142

Program and phase

SBIR · Phase II

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Fakhro, Louay K
Proposal award date
2024-05-01
Contract end date
2026-04-30
UEI
VYR3MARJVCS8
Solicitation number
NSF 23-516
Topic code
BM

Research abstract

This Small Business Innovation Research (SBIR) Phase II project addresses a pressing need for a rapid and user-friendly method to monitor blood phenylalanine levels in individuals with phenylketonuria (PKU), a lifelong genetic disorder impairing phenylalanine processing, an amino acid found in many common foods. Left untreated or poorly managed, PKU can result in intellectual disabilities, behavioral issues, and severe health complications. In the U.S., an estimated 20,000 to 35,000 individuals grapple with PKU, demanding consistent blood phenylalanine level monitoring as part of their disease management. The annual costs of PKU care can vary from $15,000 to $200,000 per individual, with higher costs linked to inadequate management, leading to irreversible damage and substantial healthcare services. Currently, monitoring occurs with intervals of 3 to 5 days or even up to two weeks, constrained by factors like test sites, facility availability, and turnaround times. Ideally, PKU monitoring should align with individual needs, occurring daily in sync with diet, age, health factors, and gestational period. Enhanced monitoring frequency is widely recognized as beneficial, and this project aims to improve PKU care by providing accessible and frequent monitoring for improved patient outcomes. This Small Business Innovation Research (SBIR) Phase II project aims to develop a rapid phenylalanine monitor for phenylketonuria (PKU) patients. The project offers rapid analysis of blood phenylalanine levels to enhance patient outcomes and improve the current standard of care. Consisting of a test strip and a test device, the system accepts a blood drop from a finger prick. The test strip conditions the blood sample with specific analytes before the test device analyzes the sample. The project's core focus is optimizing product design and system algorithms, enabling cost-effective manufacturing and deployment for end-users. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2021–2024). Reported award amounts total $1,253,142. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.